News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PAION And ErgoMed Complete Enrolment of Phase IIa Study with CNS 5161 in Opioid-Refractory Cancer Pain


12/22/2008 8:48:08 AM

AACHEN & FRANKFURT, Germany--(BUSINESS WIRE)--The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8; London AIM: PAI) and ERGOMED Clinical Research Limited today announce the completion of an open-label, single-centre Phase IIa study with PAION’s intravenous NMDA receptor antagonist CNS 5161. The study has been completed by PAION and ERGOMED under a Revenue Sharing and Co-Development Agreement signed in July 2006.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES